Dydrogesterone update: insights on its therapeutic applications

Manish Nilkanth Maladkar; Chitra Mohan Tekchandani; Sharul Sajjan Luniya

doi:10.18203/2320-1770.ijrcog20242526

Authors

Manish Nilkanth Maladkar Medical and Regulatory Affairs, Scientific department, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India
Chitra Mohan Tekchandani Department of Medical and Science, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India
Sharul Sajjan Luniya Department of Medical and Science, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242526

Keywords:

Dydrogesterone, LPD, TA, Progesterone, ART, RPL

Abstract

Progesterone deficiency is commonly implicated as an important etiology in pregnancy complications like threatened miscarriage, luteal phase defect (LPD), recurrent pregnancy loss (RPL), etc. LPD characterized by inadequate progesterone secretion during the luteal phase of the menstrual cycle, is associated with implantation failure and early pregnancy loss. Hormonal imbalances are a common element in the etiology of threatened abortion (TA) and RPL. Dydrogesterone, a synthetic progestin, has emerged as a viable treatment option in many reproduction-related disorders, including LPD, TA, RPL, and LPD associated with assisted reproductive technologies (ART). Dydrogesterone has been shown to be effective in preventing miscarriages by maintaining the corpus luteum and promoting endometrial receptivity. This up-to-date article highlights the clinical implications of dydrogesterone pertaining to its use in LPD, TA, and RPL.

Metrics

Metrics Loading ...

References

Taylor A. ABC of subfertility: extent of the problem. BMJ. 2003;327(7412):434-6.

Low Progesterone. Available at: https://my.clevelandclinic.org/health/diseases/24613-low-progesterone. Accessed on 12 June 2024.

Leth-Moller K, Hammer Jagd S, Humaidan P. The luteal phase after GnRHa trigger-understanding an enigma. Int J Fertil Steril. 2014;8(3):227-34.

Muneeba S, Acharya N, Mohammad S. The Role of Dydrogesterone in the Management of Luteal Phase Defect: A Comprehensive Review. Cureus. 2023;15(11):e48194.

Patki A, Pai H, Malik S, Duru S, Rao K. Evaluating the Role of Oral Dydrogesterone for Luteal-Phase Support in Women Undergoing Frozen Embryo Transfer: Systematic Review with Meta-Analysis. J Fertil In vitro IVF World w Reprod Med Genet Stem Cell Biol. 2023;11(2):295.

Dashti S, Eftekhar M. Luteal-phase support in assisted reproductive technology: An ongoing challenge. Int J Reprod BioMed. 2021;19:761-72.

Boutzios G, Karalaki M, Zapanti E. Common pathophysiological mechanisms involved in luteal phase deficiency and polycystic ovary syndrome Impact on fertility. Endocrine. 2013;43:314-7.

Mouri MI, Hall H, Rupp TJ. Threatened Abortion. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.

ICOG-INGNITE-Recurrent-Pregnancy-Loss-2019. Available at: https://icogonline.org/wp-content/uploads/pdf/campus/ICOG-INGNITE-Recurrent-Pregnancy-Loss-2019.pdf. Accessed on 12 June 2024.

Khanna G, Dabade M, Dutta S, Deshpande N, Mane G, Shah C, et al. Int J Reprod Contracept Obstet Gynecol. 2021;10(10):3793-8.

Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249-59.

Patki, A. Role of Dydrogesterone for Luteal Phase Support in Assisted Reproduction. Reprod Sci. 2024;31:17-29.

Nigam A. Luteal Phase Support: Why, When and How. Pan Asian J Obs Gyn. 2018;1(2):6-10.

Peng C, Huang Y, Zhou Y. Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis. Arch Gynecol Obstet. 2021;304(1):231-52.

Szekeres-Bartho J. Progesterone induced blocking factor in health and disease. Explor Immunol. 2021;1:406-17.

Vidal A, Dhakal C, Werth N, Weiss JM, Lehnick D, Kohl Schwartz AS. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone. Front. Endocrinol. 2023;14:1128564.

Ikechebelu JI, Dim CC, Eleje GU, Joe-Ikechebelu N, Okpala BC, Okam PC. A randomised control trial on oral Dydrogesterone versus micronized vaginal progesterone pessary for luteal phase support in in vitro fertilization cycles. J Med Life. 2023;16(1):62-9.

Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson JI, Driessen S, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020;15(11):e0241044.

Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertility and Sterility. 2018;109(5):756-62.

Nagarkatti R, Mehra D, Sudipa M, Archana D, Priya J, Nupur N, et al. Real-world evaluation of safety and effectiveness of Dydrogesterone in the management of threatened abortion. Int J Reprod Contracept Obstet Gynecol. 2022;11(8):2096-100.

Lou C, Wang C, Zhao Q, Jin F. Effect of Dydrogesterone and progesterone on threatened miscarriage due to corpus luteum insufficiency. Am J Transl Res. 2021;13(5):4544-52.

Zhao H, He W, Yang Z. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion. Int J Gynaecol Obstet. 2022;156(3):383-93.

Wang XX, Luo Q, Bai WP. Efficacy of progesterone on threatened miscarriage: difference in drug types. J Obstetr Gynaecol Res. 2019;45(4):794-802.

Verma S, Yadav P. To Study the Comparison Between Oral Dydrogesterone and Micronized Progesterone in Threatened Miscarriage in Terms of Pain Lower Abdomen and Bleeding Per Vaginum. Ann Int Med Den Res. 2021; 7(1):OG11-5.

Ibrahim ZM, Said ME, El Nahas KM, Younes SE, Ali TYM, Taha OT. Assessment of the Immunomodulatory Role of Dydrogesterone in Preventing Pregnancy Loss in Threatened Abortion. W J Gynecol Women’s Health. 2020;3(3):1-5.

Shaikh R, Jalbani A, Lashari S, Sangi SUN, Brohi S, Shaikh Q. Role of Micronized Progesterone vs Dydrogestron in patients with Threatened Abortion. J Soc Obstet Gynaecol Pak. 2022;12(3):262-6.

Efficacy and safety analysis of Dydrogesterone tablets in the treatment of the patients with threatened abortion due to luteal phase defect.

Bashiri A, Galperin G, Zeadna A, Baumfeld Y, Wainstock T. Increased Live Birth Rate with Dydrogesterone among Patients with Recurrent Pregnancy Loss Regardless of Other Treatments. J Clin Med. 2023;12:1967.

Anushree, Ranjan P, Singh V. A comparative study of dydrogesterone and micronized progesterone on early pregnancy loss in threatened abortion and recurrent pregnancy loss. Int J Scient Res. 2023;12(02):7-8.

Guo H, Lu Q. Efficacy of Dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(10):10971-85.

Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022;38(4):279-87.